Statistical flags indicate unusual patterns — not proof of fraud or wrongdoing. Read our methodology

Provider 1366559064

NPI: 1366559064Share
Active Billing Period:2018-012024-11(83 months)

Extreme procedure concentration — 100% of $16.9M billed through a single code

Total Paid

$16.9M

$16,901,442

Total Claims

5,644

Beneficiaries

3,155

1.8 claims/patient

Avg Cost/Claim

$3K

Monthly Spending Trend

Yearly Spending

2018
$2.3M
-30%
2019
$1.6M
+45%
2020
$2.3M
-20%
2021
$1.9M
+32%
2022
$2.5M
+24%
2023
$3.1M
+8%
2024
$3.3M

Procedure Breakdown

Cost per claim compared to national benchmarks

This provider bills for 1 distinct procedure code. The top code (Q5003 (Injection, infliximab-dyyb, biosimilar, 10 mg)) accounts for 100% of total spending.

Q5003Top 25%

Injection, infliximab-dyyb, biosimilar, 10 mg

$16.9M

5,644 claims · 100.0%

Your Cost: $2,994.59/claim|Median: $177.99
16.8× median